Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NKTR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNektar completes $350.9M equity offering, selling 4.06M shares at $92 per share
Filed April 23, 2026 · Period ending April 21, 2026 · ~1 min read
Key Changes
-
high
Nektar raised $350.9 million net proceeds by selling 4.06 million common shares at $92 each through an underwritten public offering that closed April 23, 2026. This represents approximately 4% dilution to existing shareholders.
Item 1.01, 8.01 verify on EDGAR → -
medium
Underwriters (Jefferies, TD Securities, Piper Sandler) exercised their full over-allotment option to purchase an additional 529,891 shares, bringing total offering to 4.06M shares. Full greenshoe exercise typically signals strong investor demand.
Item 1.01 verify on EDGAR → -
high
The offering was priced at $92 per share on April 21, 2026, with closing expected April 23, 2026. Net proceeds after underwriting fees and expenses total approximately $350.9 million.
Item 1.01 verify on EDGAR →
Summary
Nektar Therapeutics completed a significant capital raise, selling 4.06 million shares at $92 each for net proceeds of $350.9 million. The offering was led by three major investment banks and saw strong demand, evidenced by the underwriters exercising their full over-allotment option to purchase additional shares beyond the initial 3.5 million base offering.
For retail investors, this represents meaningful dilution of roughly 4% to the existing shareholder base, but provides Nektar with substantial cash resources. The company has not disclosed specific uses for the proceeds in this filing. The $92 pricing and full greenshoe exercise suggest the market received the offering positively.
Investors should watch for management commentary on how these funds will be deployed—whether for clinical trials, business development, debt reduction, or general corporate purposes. The next quarterly earnings call or investor presentation should provide clarity on capital allocation strategy.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 3,532,609 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) at a price to the public of $92.00 per Firm Share, less underwriting discounts and commissions.
Nektar entered into an underwriting agreement to sell 3,532,609 shares of common stock at $92.00 per share in a public offering. The underwriters also received a 30-day option to purchase an additional 529,891 shares, which they exercised in full on April 22, 2026. The offering is expected to close on April 23, 2026.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The full text of the press release announcing the pricing of the underwritten offering on April 21, 2026 is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Nektar Therapeutics announced the pricing of an underwritten public offering on April 21, 2026. The specific terms, size, and pricing details are contained in the press release attached as Exhibit 99.1. This represents a capital-raising event that will likely dilute existing shareholders but provides the company with additional funding.
Event · Item 9.01 — Financial Statements and Exhibits
Nektar Therapeutics entered into an underwriting agreement on April 21, 2026, for a securities offering with Jefferies, TD Securities, and Piper Sandler.
Added in current filing · verify on EDGAR →
Underwriting Agreement, dated April 21, 2026, between Nektar Therapeutics and Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. as representatives of the several underwriters named therein.
Nektar Therapeutics executed an underwriting agreement on April 21, 2026, with three investment banks serving as underwriters. This indicates the company is conducting a public securities offering, which typically means raising capital through the sale of stock or other securities. The specific terms, size, and pricing of the offering are not disclosed in this 8-K filing.
Added in current filing · verify on EDGAR →
Press Release dated April 21, 2026.
The company issued a press release on April 21, 2026, which is attached as an exhibit. Press releases accompanying underwriting agreements typically announce the offering details, including the number of shares and expected pricing range, though those specifics are not provided in the 8-K body itself.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify